sIgE/tIgE and IgE-FAB can be used to predict the clinical response to AIT.
ID
Bron
Verkorte titel
Aandoening
Allergic Rhinitis
Ondersteuning
Imperial College London
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Clinical response to AIT will be considered as a binary outcome (yes/no) and will be monitored by:<br>
- Control of Allergic Rhinitis and Asthma Test (CARAT) (Appendix 1). <br>
- Requirement of medication related rhinitis and/or asthma treatment. This includes oral first- and second-generation anti-histamine, nasal corticosteroid, bronchodilators, inhaled corticosteroid (ICS), and ICS + long-acting ¦Â2-agonist (LABA);<br>
- Asthma Control Questionnaire (ACQ) (Appendix 2). The MCID of the ACQ is 0.5 points.<br>
- Frequency of asthma exacerbations.
Achtergrond van het onderzoek
Rationale: Allergen Immunotherapy (AIT) has been proven to have disease-modifying properties and long-term clinical benefit after cessation in patients with or without allergic asthma. However, some patients do not respond optimally. To date there is no consensus on candidate biomarkers that are predictive of the clinical response to AIT. In addition, a recent position paper by an EAACI taskforce advises to start research initiatives in order to correlate candidate biomarkers to responders and non-responders.
Objective: We aim to identify the predictive value of the candidate biomarkers suggested by the EAACI taskforce for response to AIT. Additionally, we aim to explore novel candidate biomarkers both for clinical follow up as well as contribute to unravelling the mechanism of AIT.
Study design: This research project is twofold. Firstly: an observational, prospective cohort design to test the predictive value of the suggested biomarkers. Secondly: a case-control design to explore novel candidate biomarkers and obtain more insight in the mechanism involved in AIT.
Study population: Patients with allergic rhinitis, with or without asthma, starting AIT for the first time in their regular (outpatient) treatment. Patients will be recruited at the outpatient clinic for lung diseases and allergies.
Main study parameters/endpoints: Predictive value of candidate biomarkers sIgE/tIgE and IgE-FAB on treatment-effect.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will be asked to donate 200ml of full blood per visit (7 visits in total). This can cause a bruise or hematoma at the site of the venepuncture which is considered a low risk event. Feeling light-headedness which in some cases can lead to syncope is also a possibility. Furthermore, patients will be asked to fill out two questionnaires per visit (CARAT and ACQ), requiring ten minutes total per visit for both questionnaires.
Doel van het onderzoek
sIgE/tIgE and IgE-FAB can be used to predict the clinical response to AIT.
Onderzoeksopzet
T0 = at start of AIT
T1 = 6 months after start of AIT
T2 = 12 months after start of AIT
T3 = 2 years after start of AIT
T4 = 3 years after start of AIT (= stop AIT)
T5 = 1 year after stopping AIT
T6 = 3 years after stopping AIT
Onderzoeksproduct en/of interventie
No intervention. We collect blood through venapuncture and nasal fluid through nasal swabs.
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Positive Skin Prick Test (SPT) response of ≥ 8 mm wheal diameter and/or serum allergen-specific IgE levels higher than 0.70 kU/L to grass pollen, tree pollen and/or house dust mite (HDM) extract.
- Minimum of 16 years of age and a confirmed clinical diagnosis of allergic rhinitis.
- Clinical indication for AIT (according to EAACI guidelines).
Signed and dated informed consent (IC) form by a legally competent participant.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
History of chronic autoimmune disease (aside from asthma, atopic dermatitis or allergic rhinitis) which may interfere with results.
Use of an antihistamines or decongestant therapy 7 days prior to screening visit.
Prior exposure to any monoclonal antibody treatment within the past 12 months.
Contraindication to sublingual or subcutaneous AIT.
Current immunosuppressive treatment.
Previous immunotherapy with grass pollen, tree pollen or house dust mite extract.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7312 |
| NTR-old | NTR7528 |
| CCMO | NL67580.100.18 |
| OMON | NL-OMON45948 |